Q4 2021 Earnings

Revenue

$4M+15.2% YoY

Gross Profit

$3M76.8% margin

Operating Income

-$4M-93.0% margin

Net Income

-$4M-96.9% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

-6.4%

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

Total Assets

$66M

Total Liabilities

$17M

Stockholders' Equity

$49M

Cash & Equivalents

$54M

Metric	Current	Year Ago	Change
Revenue	$4M	$4M	+15.2%
Gross Profit	$3M	$2M	+44.0%
Operating Income	-$4M	-$2M	-75.8%
Net Income	-$4M	-$2M	-162.3%

Functional Neurosurgery Navigation and Therapy

$2M33%

Biologics and Drug Delivery Revenue

$2M26%

Biologics and Drug Delivery - Disposable Products

$852,00013%

Biologics and Drug Delivery - Services

$837,00013%

Capital Equipment and Software Revenue

$454,0007%

Capital Equipment and Software - Systems and Software Products

$284,0004%

Capital Equipment and Software - Services

$170,0003%